Contributions
Abstract: EP1751
Type: ePoster
Abstract Category: Therapy - disease modifying - 29 Risk management for disease modifying treatments
Introduction: Dimethyl fumarate is an oral compound indicated for the treatment of adult patients with relapsing remitting multiple sclerosis. Adherence to treatment may be impacted by the route of administration as well as side effects. Although the neurologist remains the primary point-of-contact for MS patients, the retail pharmacist has the opportunity to play a key role by providing individually tailored information at the beginning of treatment. The TECPHIE study aims to assess the impact on adherence of motivational interviews provided by community pharmacists in France.
Materials and method: TECPHIE is a 12-month, randomized, prospective multicentre study examining two groups of pharmacists: one providing periodic motivational interviews in addition to the usual drug delivery, and one delivering drug in the standard manner. Motivational interviews consist of discussions of different topics in response to patient requests (information about treatment, side effects, or disease; and advice for daily living). The primary criteria for evaluation is the Medication Possession Ratio (MPR) at 12 months. Several secondary endpoints will be evaluated, such as persistence to treatment, use of medical resources, patient satisfaction with treatment measured by the TSQM (Treatment Satisfaction Questionnaire for Medication), and patient satisfaction with pharmaceutical interviews. The required patient sample size of 150 (75 per group) was calculated based on an estimated adherence of 70% in usual care and an increase of 15 to 20% in interview group.
Results: Recruitment began in December 2016. At present, 35 pharmacists have been recruited and 24 patients enrolled. Baseline results will be presented.
Conclusion: This study will be able to rigorously assess the impact on adherence of information provided by pharmacists to adult patients with relapsing remitting multiple sclerosis treated by dimethyl fumarate.
Disclosure:
Yves Michiels: member of the scientific committee of the TECPHIE study and investigator of the study, he has received honoraria for it from Biogen France SAS; Novartis, MSD
Patrick Tilleuk: member of the scientific committee of the TECPHIE study, he has received honoraria for it from Biogen France SAS;
Hubert Méchin: employees of Observia, which has a research consultancy agreement with Biogen France SAS;
Florence Hammes: employee of Biogen France SAS.
Abstract: EP1751
Type: ePoster
Abstract Category: Therapy - disease modifying - 29 Risk management for disease modifying treatments
Introduction: Dimethyl fumarate is an oral compound indicated for the treatment of adult patients with relapsing remitting multiple sclerosis. Adherence to treatment may be impacted by the route of administration as well as side effects. Although the neurologist remains the primary point-of-contact for MS patients, the retail pharmacist has the opportunity to play a key role by providing individually tailored information at the beginning of treatment. The TECPHIE study aims to assess the impact on adherence of motivational interviews provided by community pharmacists in France.
Materials and method: TECPHIE is a 12-month, randomized, prospective multicentre study examining two groups of pharmacists: one providing periodic motivational interviews in addition to the usual drug delivery, and one delivering drug in the standard manner. Motivational interviews consist of discussions of different topics in response to patient requests (information about treatment, side effects, or disease; and advice for daily living). The primary criteria for evaluation is the Medication Possession Ratio (MPR) at 12 months. Several secondary endpoints will be evaluated, such as persistence to treatment, use of medical resources, patient satisfaction with treatment measured by the TSQM (Treatment Satisfaction Questionnaire for Medication), and patient satisfaction with pharmaceutical interviews. The required patient sample size of 150 (75 per group) was calculated based on an estimated adherence of 70% in usual care and an increase of 15 to 20% in interview group.
Results: Recruitment began in December 2016. At present, 35 pharmacists have been recruited and 24 patients enrolled. Baseline results will be presented.
Conclusion: This study will be able to rigorously assess the impact on adherence of information provided by pharmacists to adult patients with relapsing remitting multiple sclerosis treated by dimethyl fumarate.
Disclosure:
Yves Michiels: member of the scientific committee of the TECPHIE study and investigator of the study, he has received honoraria for it from Biogen France SAS; Novartis, MSD
Patrick Tilleuk: member of the scientific committee of the TECPHIE study, he has received honoraria for it from Biogen France SAS;
Hubert Méchin: employees of Observia, which has a research consultancy agreement with Biogen France SAS;
Florence Hammes: employee of Biogen France SAS.